GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (NAS:MREO) » Definitions » 14-Day RSI

Mereo BioPharma Group (Mereo BioPharma Group) 14-Day RSI : 39.88 (As of Apr. 30, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Mereo BioPharma Group 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-04-30), Mereo BioPharma Group's 14-Day RSI is 39.88.

The industry rank for Mereo BioPharma Group's 14-Day RSI or its related term are showing as below:

MREO's 14-Day RSI is ranked better than
71.9% of 1573 companies
in the Biotechnology industry
Industry Median: 46.35 vs MREO: 39.88

Competitive Comparison of Mereo BioPharma Group's 14-Day RSI

For the Biotechnology subindustry, Mereo BioPharma Group's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mereo BioPharma Group's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's 14-Day RSI falls into.



Mereo BioPharma Group  (NAS:MREO) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mereo BioPharma Group  (NAS:MREO) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Mereo BioPharma Group 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Mereo BioPharma Group (Mereo BioPharma Group) Business Description

Traded in Other Exchanges
Address
One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.